




Figure S1 Diagram of subgroup classifications of HGNEC. HGNEC, high-grade neuroendocrine carcinoma.

Table S1 Clinical staging of patients

Characteristic	Total (n=921)	LCNEC (n=341)	SCLC (n=580)
cT stage			
T1–2	676 (73.4)	252 (73.9)	424 (73.1)
T3–4	188 (20.4)	65 (19.1)	123 (21.2)
Tx	57 (6.2)	24 (7.0)	33 (5.7)
cN stage			
N0	535 (58.1)	216 (63.3)	319 (55.0)
N1–2	242 (26.3)	65 (19.1)	177 (30.5)
N1	145 (15.7)	40 (11.7)	105 (18.1)
N2	97 (10.5)	25 (7.3)	72 (12.4)
Nx	144 (15.6)	60 (17.6)	84 (14.5)
cTNM stage			
I	343 (37.2)	135 (39.6)	208 (35.9)
II	260 (28.2)	76 (22.3)	184 (31.7)
III	151 (16.4)	59 (17.3)	92 (15.9)
Unknown	167 (18.1)	71 (20.8)	96 (16.5)

Data are presented as n (%). LCNEC, large-cell neuroendocrine carcinoma; SCLC, small-cell lung cancer; cTNM stage, clinical tumor-node-metastasis staging.

Table S2 Comparison of baseline characteristics between Stage I LCNEC and SCLC groups

Characteristic	Total (n=314)	LCNEC (n=153)	SCLC (n=161)	P
Gender				0.21
Male	278 (88.5)	141 (92.2)	137 (85.1)	
Female	36 (11.5)	12 (7.8)	24 (14.9)	
Age (years)				0.53
<65	170 (54.1)	82 (53.6)	88 (54.7)	
≥65	144 (45.9)	71 (46.4)	73 (45.3)	
Smoking history				0.048
Yes	220 (70.1)	101 (66.0)	119 (73.9)	
No	94 (29.9)	52 (34.0)	42 (26.1)	
Resection type				0.15
VATS	305 (97.1)	146 (95.4)	159 (98.8)	
Robotic-assisted	9 (2.9)	7 (4.6)	2 (1.2)	
Primary site				0.001
Upper lobe	155 (49.4)	97 (63.4)	58 (36.0)	
Middle lobe	33 (10.5)	7 (4.6)	26 (16.1)	
Lower lobe	126 (40.1)	49 (32.0)	77 (47.9)	
Laterality				0.18
Left	150 (47.8)	70 (45.8)	80 (49.7)	
Right	164 (52.2)	83 (54.2)	81 (50.3)	
Tumor location				<0.001
Central	134 (42.7)	24 (15.7)	110 (68.3)	
Peripheral	180 (57.3)	129 (84.3)	51 (31.7)	
pT stage				0.43
T1	196 (62.4)	84 (54.9)	112 (69.6)	
T2	118 (37.6)	69 (45.1)	49 (30.4)	
VPI				0.001
With	202 (64.3)	58 (37.9)	144 (89.4)	
Without	112 (35.7)	95 (62.1)	17 (10.6)	
LVI				0.77
With	48 (15.3)	23 (15.0)	25 (15.5)	
Without	266 (84.7)	130 (85.0)	136 (84.5)	
Adjuvant chemotherapy				<0.001
Yes	222 (70.7)	96 (62.7)	125 (77.6)	
EP/EC	152 (48.4)	44 (28.7)	117 (72.7)	
AC/AP, TC/TP	52 (16.6)	36 (23.5)	6 (3.7)	
Others	18 (5.7)	16 (10.5)	2 (1.2)	
No	92 (29.3)	57 (37.3)	36 (22.4)	

Data are presented as n (%). LCNEC, large-cell neuroendocrine carcinoma; SCLC, small-cell lung cancer; VATS, video-assisted thoracoscopic surgery; pTNM stage, pathological tumor-node-metastasis staging; VPI, visceral pleural invasion; LVI, lymphovascular invasion; EP/EC, etoposide plus cisplatin or carboplatin; TC/TP, paclitaxel plus cisplatin or carboplatin; AC/AP, pemetrexed plus cisplatin or carboplatin.